Allara raises US$30m to improve access to hormonal and reproductive healthcare

Allara has raised US$30m to develop AI tools, expand access to women’s healthcare and fund research, bringing its total funding to US$75m.

The US virtual healthcare company provides integrated care for hormonal, metabolic and reproductive conditions.

In a survey of more than 1,600 women joining Allara, 58 per cent had already consulted at least two healthcare providers about their symptoms.

Of those who had previously seen another provider, 80 per cent said their symptoms had been dismissed or minimised.

Among women who had tried weight-management medication, 30 per cent said they had stopped taking a medication because their provider did not support them.

Rachel Blank, founder and chief executive of Allara, said: “Women don’t avoid care because they don’t care about their health. They avoid it because they have needs that go well beyond an annual visit.”

“We built Allara to treat women’s health as connected, because hormones, metabolism and life stage don’t work in isolation.

“We’ve proven that model works at scale and can be covered by insurance.

“AI enhanced workflows for our providers makes it far more powerful: faster for our clinicians, easier for our patients, and available to millions more women who deserve a better healthcare experience.”

Allara pairs women’s health clinicians with registered dietitians to provide medical, nutritional and lifestyle support through one platform.

The company said more than 120,000 women have received care through its services.

According to its patient data, 73 per cent of patients with obesity, defined as a body mass index (BMI) above 30, who had received care for at least six months lost weight.

Of these patients, 48 per cent lost at least 5 per cent of their body weight, a threshold associated with clinically meaningful health improvements, while 28 per cent lost 10 per cent or more.

Among members with irregular menstrual cycles, 69 per cent reported improved regularity.

In patient surveys, 89 per cent said they felt supported in making positive health changes, while 78 per cent reported positive changes to their diet.

This year, Allara expanded its services to include GLP-1 medications alongside lifestyle and nutrition guidance, and perimenopause care incorporating hormone replacement therapy.

It also introduced prescription skincare and hair loss treatments for symptoms associated with hormonal conditions.

The company launched virtual urgent care for bacterial vaginosis (BV), urinary tract infections (UTIs) and sexually transmitted infection (STI) testing.

The new investment will support AI tools for patient intake, scheduling and ongoing treatment management.

Allara said its existing digital systems support clinicians delivering virtual care. The planned expansion is intended to give clinicians more time with patients while keeping healthcare professionals responsible for treatment decisions.

The company said patient data is encrypted and secured.

Allara already provides access through major health insurers in most US states. It plans to expand its relationships with healthcare providers and other organisations alongside its existing employer partnerships.

The funding will also support research using real-world patient data to investigate conditions including polycystic ovary syndrome (PCOS), thyroid disorders and endometriosis, as well as postpartum and perimenopausal health.

Allara said it is developing published research based on patient insights to address gaps in evidence around women’s health.

Five existing investors, including Index Ventures and GV, increased their commitments in the US$30m round. New investors include Camino Partners, Foreground Capital and Family Fund.

Elle Lanning, president at Camino Partners, said: “Allara is delivering an exceptional care experience for women whose complex needs have fallen through the cracks in the traditional healthcare system.

“Rachel and her team have built an approach that meets women where they are, takes their conditions seriously, and consistently delivers outcomes through a unique multidisciplinary care model.”